In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.

What’s needed now is an all-of-the-above approach. Use every avenue possible to reduce carbon intensity today, tailoring ...

Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a ...

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

Tonabersat (HCB-1019) is under development for the treatment of diabetic macular edema (DME),Post-Acute Sequelae of COVID 2019 ... Inflammx Therapeutics is developing small molecule therapeutics for ...

Tonabersat (HCB-1019) is under development for the treatment of diabetic macular edema (DME),Post-Acute Sequelae of COVID 2019 ... Inflammx Therapeutics is developing small molecule therapeutics for ...